Plexiform Neurofibroma

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

Natural History Study of Patients With Neurofibromatosis Type I

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

A Study of Avutometinib for People With Solid Tumor Cancers

Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas

Neurofibromatosis Type 1 Tumor Early Detection Study

Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1

Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)

Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours

PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)

Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Study of PEG-Intron for Plexiform Neurofibromas

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas